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Background: Maternal obesity and gestational diabetes mellitus (GDM) may independently influence offspring fat
mass and metabolic disease susceptibility. In this pilot study, body composition and fat distribution in offspring
from obese women with and without GDM and lean women were assessed within the 1st year of life, and
maternal and newborn plasma factors were related to offspring adipose tissue distribution.
Methods: Serum and plasma samples from pregnant obese women with (n = 16) or without (n = 13) GDM and
normoglycemic lean women (n = 15) at 3rd trimester and offspring cord plasma were used for analyzing lipid
profiles, insulin and adipokine levels. At week-1 and 6, month-4 and year-1, offspring anthropometrics and skinfold
thickness (SFT) were measured and abdominal subcutaneous (SCA) and preperitoneal adipose tissue (PPA) were
determined by ultrasonography.
Results: Cord insulin was significantly increased in the GDM group, whereas levels of cord leptin, total and high
molecular weight (HMW) adiponectin were similar between the groups. Neonates of the GDM group showed
significantly higher SFT and fat mass until week-6 and significantly increased SCA at week-1 compared to the lean
group that persisted as strong trend at week-6. Interestingly, PPA in neonates of the GDM group was significantly
elevated at week-1 compared to both the lean and obese group. At month-4 and year-1, significant differences in adipose
tissue growth between the groups were not observed. Multiple linear regression analyses revealed that cord insulin levels
are independently related to neonatal PPA that showed significant relation to PPA development at year-1. Maternal fasted
C-peptide and HMW adiponectin levels at 3rd trimester emerged to be determinants for PPA at week-1.
Conclusion: Maternal pregravid obesity combined with GDM leads to newborn hyperinsulinemia and increased offspring
fat mass until week-6, whereas pregravid obesity without GDM does not. This strongly suggests the pivotal role of GDM
in the adverse offspring outcome. Maternal C-peptide and HMW adiponectin levels in pregnancy emerge to be predictive
for elevated PPA in newborns and might be indicative for the obesity risk at later life. Altogether, the findings from our
pilot study warrant evaluation in long-term studies.
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Emerging data suggest a permanent impact of the perinatal
environment on the offspring risk for developing obesity,
metabolic and cardiovascular diseases. The prevalence
of obesity in US children and adolescents was 16.9% in
2009–2010 [1], while a German survey showed slightly
lower rates [2]. Particularly worrying is the continuous
increase in obesity prevalence within young women show-
ing that more than 20.5% of US women at reproductive age
were obese (BMI > 30 kg/m2) in 2009 [3]. A similar trend
was recently reported for the German population [4].
Pregravid obesity is, besides maternal age, ethnicity
and family history of diabetes, also a major predictor for
gestational diabetes mellitus (GDM) [5]. Importantly,
maternal obesity and GDM are independent risk factors
for fetal hyperinsulinemia, elevated weight and body fat at
birth, suggesting that both GDM and pregravid obesity
influence fetal development through similar mechanism
[6-8]. Moreover, children born from obese and/or diabetic
mothers are at higher risk for obesity and insulin resistance/
type 2 diabetes from childhood periods [9-11] and adoles-
cence [11,12] up to adulthood [13,14].
There is rising evidence from infants and adults that
the distribution of fat depots is a stronger predictor for
the metabolic and cardiovascular risk than the total
amount of fat [15,16]. Notably, visceral fat has been asso-
ciated with insulin resistance, decreased adiponectin and
hypertriglyceridemia in children and adolescents [17].
Recently, ultrasonography was considered as a valid method
for measuring infant abdominal fat distribution in clinical
research [18,19]. Preperitoneal adipose tissue (PPA) assessed
by ultrasonography has been proposed as a surrogate
for visceral/intra-abdominal fat. However, there is missing
information about metabolic markers, e.g. insulin, leptin
and adiponectin, associated with the distribution of ab-
dominal subcutaneous (SCA) adipose tissues and PPA
in neonates and early infancy.
This pilot study comprised pregravid obese women
with and without GDM and lean pregnant women, as well
as their offspring. Maternal and umbilical cord plasma
metabolic markers were determined and related to offspring
anthropometrics and distribution of adipose tissues, skin-
fold thickness (SFT) and abdominal SCA and PPA, from
birth/week-1 up to year-1 post partum (pp).
Methods
Study population
The study protocol of the GesA-Study (Gestational diabetes
mellitus and adiposity in early adipose tissue development)
was approved by the Ethics Committee of the Technische
Universität München (Ethics Committee Number: 2629/
09) and was registered at the German clinical trials register
(DRKS00004370). Singleton pregnant women were recruited
at the Abteilung für Geburtshilfe und Perinatalmedizinder Frauenklinik, Klinikum rechts der Isar, Technische
Universität München, Munich, Germany between week-
33 and 36 of gestation. Written informed consent was
obtained from participants before their first appointment.
Exclusion criteria for pregnant women were preeclampsia,
chronic hypertension and pregravid type 1 or type 2 dia-
betes. At delivery, participants were excluded if newborns
were born preterm (< 37 weeks of gestation), small for
gestational age (SGA) or with an APGAR < 5. The study
group consisted of Caucasian pregnant women divided
into three groups according to their self-reported pre-
gravid BMI and the result of the oral glucose tolerance
tests in the 2nd and 3rd trimester [normoglycemic lean
(BMI 18.5-25 kg/m2; n = 15), obese women without
GDM (BMI > 30 kg/m2; n = 13), and obese women with
GDM (BMI > 30 kg/m2; diet-controlled n = 7, insulin-
treated n = 9)]. The diagnosis of GDM was defined accord-
ing to the Hyperglycemia and Pregnancy Outcome (HAPO)
criteria [20]: fasting glucose > 5.1 mmol/L (92 mg/dL),
1 h glucose > 10 mmol/L (180 mg/dL), 2 h glucose >
8.5 mmol/L (153 mg/dL). GDM was diagnosed if at least
1 of the threshholds was met or exceeded. Women, tested
negatively in the OGTT in 2nd trimester, were retested in
the 3rd trimester to confirm glucose tolerance and to re-
evaluate their group allocation.
Biochemical analysis
Venous blood samples were obtained from fasted women
between week-33 and 36 of gestation. Neonatal blood was
collected immediately after delivery from umbilical cord
vein. At Synlab (Munich, Germany), maternal and cord
plasma glucose were assessed by the glucose oxidase
method, and maternal and fetal serum lipid parameters
(total, LDL and HDL cholesterol, triglycerides) were
determined using established enzymatic methods (Roche
Diagnostics, Mannheim, Germany). Fasted maternal
plasma and cord plasma insulin as well as fasted maternal
plasma C-peptide were analyzed using commercially avail-
able ELISAs (Dako, Glostrup, Denmark). Maternal insulin
sensitivity was assessed according to the formula for the
homeostasis model of assessment-insulin resistance:
HOMA-IR-index = [Insulin (μU/mL) × Glucose (mmol/
L)]/22.5. Maternal and cord plasma levels for leptin (R&D
Systems, Minneapolis, USA), total adiponectin and HMW
adiponectin (ALPCO, Salem, NH, USA) were determined
by ELISA. The ratio of high molecular weight (HMW) to
total adiponectin (SA) was calculated for each plasma
sample. All calculated intra- and interassay coefficients of
variation (CV) were less than 10%.
Measurements of anthropometric parameters and
adipose tissue distribution
Anthropometric data and SFT were assessed as origin-
ally described by Hauner et al. [21]. Briefly, birth weight,
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obstetric protocol. At visit week-6, month-4 and year-1 pp,
the infant weight and height, head circumference, and
waist circumference (only at year-1) were determined in
the study center. Ponderal index (in kg/m3) was calculated
according to the measured variables.
SFT measurements were conducted by one well-trained
researcher at 2–5 days pp in the obstetric clinic as well as
at week-6, month-4 and year-1 pp at the study center.
SFTs were determined in triplicate with a Holtain caliper
(Holtain Ltd, Crosswell, Crymych, UK) at the infant’s
left body axis at the following four sites: triceps, biceps,
subscapular and suprailiac. Total body fat was calculated
via predictive SFT equation according to the method of
Westrate and Deurenberg [22] and trunk-to total SFT (%)
was evaluated by applying the equation (subscapular +
suprailiac SFT)/(sum of 4 SFTs) × 100 [23].
Ultrasonographic imaging, as described originally by
Holzhauer et al. [18] was performed by two researchers
(including one pediatrician blinded to study group allo-
cation) at week-1, week-6, month-4 and year-1. Briefly,
abdominal SCA and PPA fat thicknesses were measured
in sagittal planes as areas of 1-cm length just below the
xiphoid process. Additionally, SCA was determined in
axial planes as areas of 1-cm length in the middle of the
xiphoid process and the navel directly above the linea
alba. From each plane, three images were analyzed by
one observer and 120 images were randomly controlled by
a completely blinded second researcher. The inter-observer
variability was calculated by interclass coefficient (ICC)
and further validated by a Bland-Altman plot [24]. The
ICC for the ultrasonographic analysis was 0.981 and
the p-value < 0.001, indicating high correlation be-
tween independent assessments. In the Bland-Altman
plot analysis, the mean of the differences (bias) between
observers was −0.17 mm2 and the Limits of Agreement
were −0.65 mm2 (mean −2 SD) and 0.31 mm2 (mean +2
SD), excluding a systematic inter-observer bias (Additional
file 1).
Statistical analysis
For all statistical analyses, IBM SPSS statistics software
(version 20.0; IBM Corp.) was used. One-way ANOVA
with Sidak’s post hoc test was applied for group com-
parison of normally distributed variables and data are
presented as means ± SD. In case of violation of the
normality assumption, the Kruskal-Wallis test with
Dunn’s post hoc test was applied, and accordingly, data
are presented as medians and interquartile ranges. The
Fisher’s Exact test was used for analyzing qualitative
measurements. Comparative statistical evaluation of in-
fant growth and fat development between the groups
was performed by employing multiple linear regression
models. The potential confounding factors offspring sexand pregnancy duration were taken into account when
analyzing cord parameters and the covariate infant age
at investigation was additionally applied for respective
anthropometric and adipose tissue growth assessments.
Generally, infant parameters at week-6, month-4 and
year-1 were further adjusted for breastfeeding status.
Linear regression analyses were used to identify maternal
parameters and cord insulin levels independently related to
offspring adipose tissue distribution. If necessary, logarith-
mically transformed variables were applied to accomplish
normality of residuals. Values for the unadjusted analyses
are presented, whereas the indicated adjusted model
considered the variables offspring sex, gestational dur-
ation, maternal pre-pregnancy BMI, area under the curve
(AUC) Glucose (OGTT) and gestational weight gain. Apply-
ing adipose tissue markers at week-6, month-4 and year-1
as dependent variables, corresponding breastfeeding status
was a further covariate. Spearman correlation analysis was
used to determine the association of cord adiponectin
levels with respective cord insulin levels and adipose tissue
parameters at week-1, and respective partial correlations
were applied including the covariables for infant sex, preg-
nancy duration, maternal pre-pregnancy BMI, AUC Glucose
(OGTT) and gestational weight gain. All statistical tests
were performed two-sided and a p-value < 0.05 was con-
sidered to indicate statistical significance.
Results
Maternal and fetal metabolic outcome
The main clinical and metabolic data of the study popu-
lation are summarized in Table 1. Lean and obese
participants with and without GDM did not significantly
differ in parity or mode of delivery, but obese partici-
pants with GDM were slightly older at study entry, and
pregnancy duration was shorter compared to obese sub-
jects without GDM. Both obese groups had similar preg-
ravid BMI and weight gain during pregnancy, whereas
the glucose levels (fasted, 1 h, 2 h) upon OGTT were
significantly higher in the obese GDM group than in the
obese group without GDM. At baseline (week-33 to 36
of gestation), obese women with and without GDM had
significantly increased levels of fasting insulin and C-
peptide compared to lean subjects and showed increased
insulin resistance estimated by HOMA-IR-index. HbA1c
levels were similar between all groups. Plasma leptin levels
of obese pregnant women were - irrespective of GDM -
significantly higher, while HMW-total adiponectin ratios
(SA) were significantly lower compared to the lean group.
Concerning the lipid profile, total cholesterol levels
were significantly decreased in obese subjects, but
HDL cholesterol and triglyceride levels were similar
between study groups. Cord plasma insulin levels and
HOMA-IR-index were significantly elevated in the
obese group with GDM compared to the euglycemic
Table 1 Characterization of study participants
A Mother Lean group Obese group Obese GDM group P-value1
Number of women (n = 44) 15 13 16
Age (year) 31.1 ± 3.1 28.5 ± 4.2 32.6 ± 4.8 0.040c
Primiparae (%) [n] 86.7 [13] 76.9 [10] 56.2 [9] 0.299
BMI (kg/m2) before pregnancy 20.1 (19.5-22.0) 36.1 (32.2-38.3) 33.4 (31.1-36.1) < 0.001a,b
Gestational weight gain (kg) 16.8 ± 4.4 11.6 ± 5.6 12.1 ± 5.8 0.022a,b
Parental history of diabetes (%) [n] 13.3 [2] 38.5 [5] 43.8 [7] 0.181
Duration of pregnancy (days) 278.2 ± 8.1 279.5 ± 8.2 271.3 ± 7.0 0.012c
Mode of delivery
Spontaneous / cesarean section, n 9/6 6/7 6/10 0.483
75 g OGTT (mmol/L)
Glucose fasted 4.22 (3.89-4.39) 4.33 (4.00-4.63) 5.11 (4.44-5.56) < 0.001b,c
Glucose 1 h 7.41 ± 0.90 7.34 ± 1.42 10.85 ± 1.34 < 0.001b,c
Glucose 2 h 6.30 ± 0.96 6.49 ± 1.21 8.00 ± 1.57 < 0.001b,c
Area under curve (AUC) Glucose 12.54 (11.90-13.24) 11.85 (11.65-14.10) 16.37 (16.04-18.13) < 0.001
b,c
Fasted plasma/serum parameters at 3rd trimester
Gestational age (weeks) 33.9 ± 1.4 34.3 ± 1.7 34.1 ± 1.0 0.836
Glucose (mmol/L) 4.10 ± 0.32 4.19 ± 0.40 4.39 ± 0.28 0.161
Insulin (μU/mL) 5.66 (4.76-10.05) 11.54 (9.28-20.54) 13.99 (11.22-17.97) 0.002a,b
HOMA-IR-index 1.10 (0.86-1.79) 2.31 (1.98-4.15) 2.76 (2.08-3.63) 0.001a,b
C-peptide (ng/mL) 1.60 (1.42-2.23) 2.99 (2.05-3.51) 3.01 (2.64-3.14) 0.002a,b
HbA1c (%) 5.32 ± 0.31 5.45 ± 0.23 5.40 ± 0.28 0.474
Leptin (ng/mL) 9.30 (6.52-20.11) 46.03 (29.84-78.67) 42.24 (26.71-66.69) < 0.001a,b
Total adiponectin (μg/mL) 4.98 ± 1.02 4.14 ± 1.78 3.81 ± 1.39 0.071
HMW adiponectin (μg/mL) 2.86 ± 0.82 2.06 ± 1.17 1.74 ± 0.91 0.008b
SA 0.57 ± 0.1 0.48 ± 0.09 0.44 ± 0.07 < 0.001
a,b
Total cholesterol (mmol/L) 7.49 ± 1.51 6.28 ± 0.96 6.60 ± 0.96 0.035a
LDL cholesterol (mmol/L) 4.86 ± 1.50 3.73 ± 0.87 3.92 ± 1.96 0.039
HDL cholesterol (mmol/L) 1.92 ± 0.49 1.73 ± 0.45 1.88 ± 0.28 0.524
Triglycerides (mmol/L) 2.53 ± 0.74 2.38 ± 0.57 2.76 ± 0.72 0.420
B Infant Lean group Obese group Obese GDM group P-value1 Adjusted p-value2
Offspring gender (male/female), n 8/7 8/5 13/3 0.275
Umbilical cord plasma parameters
Glucose (mmol/L) 4.46 ± 1.13 4.42 ± 1.03 4.60 ± 1.02 0.892 0.202
Insulin (μU/mL) 1.72 (1.08-5.14) 1.73 (1.33-3.97) 5.29 (4.21-8.33) 0.023b,c 0.014b,c
HOMA-IR-index 0.40 (0.22-1.23) 0.42 (0.23-0.74) 1.08 (0.81-1.52) 0.021b,c 0.009b,c
Leptin (ng/mL) 5.88 (2.15-9.70) 7.57 (4.56-16.65) 6.84 (4.76-11.58) 0.455 0.114
Total adiponectin (μg/mL) 20.68 ± 6.23 20.82 ± 8.56 22.03 ± 7.33 0.977 0.685
HMW adiponectin (μg/mL) 14.61 ± 5.15 14.28 ± 7.02 14.75 ± 5.80 0.860 0.884
SA 0.70 ± 0.06 0.67 ± 0.06 0.65 ± 0.08 0.292 0.348
Total cholesterol (mmol/L) 1.71 (1.31-1.90) 1.53 (1.36-1.71) 1.55 (1.32-1.73) 0.718 0.886
LDL cholesterol (mmol/L) 0.54 (0.32-0.65) 0.52 (0.38-0.60) 0.47 (0.41-0.54) 0.905 0.271
HDL cholesterol (mmol/L) 0.72 (0.67-1.03) 0.62 (0.60-0.96) 0.72 (0.57-0.88) 0.691 0.724
Triglycerides (mmol/L) 0.35 (0.27-0.52) 0.35 (0.26-0.45) 0.40 (0.25-0.46) 0.959 0.847
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Table 1 Characterization of study participants (Continued)
Breastfeeding status at week-6 (month-4), n
Exclusively breastfed 10 (8) 7 (6) 6 (4) 0.257 (0.304)
Formula and breast milk 0 (2) 3 (0) 4 (4)
Formula only 5 (5) 3 (6) 4 (6)
Introduction of solid food (months) 5.0 (5.0-6.0) 5.0 (4.0-6.0) 5.0 (4.0-6.0) 0.411
HbA1c: hemoglobin A1c; HDL: high-density lipoprotein; HOMA-IR: homeostasis model assessment-insulin resistance; LDL: low-density lipoprotein; OGTT: oral
glucose tolerance test; SA: HMW-total adiponectin ratio.
Data are presented as mean ± SD; otherwise skewed variables are presented as median followed by interquartile range.
1One-way ANOVA with Sidak’s post hoc test or nonparametric Kruskal-Wallis-test with Dunn’s post hoc test.
2Statistical analyses for cord plasma parameters were performed by multiple linear regression models and p-values were adjusted for infant sex and
pregnancy duration.
aP-value < 0.05 obese vs. lean group; bp-value < 0.05 obese GDM vs. lean group; cp-value < 0.05 obese GDM vs. obese group.
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ences were observed for cord plasma HMW and total
adiponectin or SA between all study groups. In addition,
levels of LDL, HDL, and total cholesterol as well as tri-
glycerides were similar in all groups. With regard to
breastfeeding status at week-6 and month-4 and the intro-
duction of solid food, no significant differences were ob-
served between the study groups.
Infant anthropometrics, adipose tissue growth and
distribution
Infant anthropometrics and adipose tissue development
assessed by SFT measurement and ultrasonography from
birth/week-1 to year-1 are shown in Tables 2 and 3, re-
spectively. Anthropometric birth outcomes, namely
weight, height, ponderal index and head circumference
were similar for all groups. However, the sum of 4 SFT
at week-1 was significantly higher in the obese GDM
group than in the lean group after considering the po-
tential confounders infant sex, pregnancy duration and
age at investigation. Similarly, abdominal SCA was sig-
nificantly elevated in the newborns of obese mothers
with GDM compared to the lean group, whereas PPA
was significantly increased compared to the normogly-
cemic lean and obese group. At week-6, only SFT and
calculated fat mass were significantly higher in the
obese group with GDM after considering indicated
confounders. In contrast, SCA and PPA were not sig-
nificantly larger in offspring of obese mothers with
GDM at week-6. Notably, although the sum of all 4
SFT did not differ significantly between groups at year-
1, the trunk-total SFT ratio was significantly higher in
obese GDM offspring than in children of both euglyce-
mic groups, indicating changes in adipose tissue distri-
bution with increased trunk fat in these infants. With
regard to further anthropometric and adipose tissue
parameters at month-4 and year-1 and total weight and
fat mass gain from birth to year-1, no significant
differences were observed between the three groups
(Tables 2 and 3).Relation of cord plasma insulin to offspring fat
distribution up to year-1
Linear regression analyses were used to explore the rela-
tion of cord plasma insulin to infant SFT, SCA and PPA at
all ages investigated (Table 4). Thus, cord insulin levels
were positively related to SFT at week-1 in the unadjusted
analysis, however, in the adjusted model, the relationship
did not remain significant (p = 0.071). After repeating the
linear regressions with abdominal SCA and PPA at week-1,
respectively, cord insulin levels also emerged as positive
determinant for both adipose tissue markers in the un-
adjusted analysis (Table 4). This independent relationship
still remained after adjusting for infant sex, pregnancy
duration, maternal pre-pregnancy BMI, AUC Glucose
(OGTT) and gestational weight gain. No significant rela-
tionships were found between cord insulin levels and fat
distribution at week-6, month-4 and year-1 in the fully ad-
justed analyses (Table 4).
Relation of infant anthropometric parameters at birth/
week-1 to respective year-1 measures
The influence of neonatal anthropometric parameters on
corresponding primary endpoint parameters at year-1 were
evaluated by linear regression. The adjusted analysis was
further performed with the covariates infant sex, pregnancy
duration, breastfeeding status at month-4, pre-pregnancy
BMI, AUC Glucose (OGTT) and gestational weight gain
(Table 5). Values for PPA at week-1 emerged as positive
independent determinants of PPA at year-1 in both
analyses. In contrast, no further significant relationships
were observed between birth weight, ponderal index, SFT
and SCA assessed at year-1 and respective parameters
determined at birth/week-1.
Relation of maternal plasma C-peptide and adiponectin
to offspring fat distribution up to year-1
Linear regression analyses were conducted to determine
the relationship of maternal fasted C-peptide, HMW
adiponectin levels and SA at 3rd trimester with neonatal
PPA at week-1 (Figure 1). For maternal C-peptide, a
Table 2 Anthropometric infant data from birth to year-1
Lean group Obese group Obese GDM group P-value1 Adjusted p-value2
Weight [g]
Birth 3,449 ± 332 [15] 3,651 ± 285 [13] 3,617 ± 333 [16] 0.201 0.169
Week-6 4,701 ± 330 [15] 4,963 ± 635 [13] 5,285 ± 517 [12] 0.017b 0.170
Month-4 6,468 ± 522 [15] 6,929 ± 829 [11] 7,066 ± 732 [13] 0.071 0.211
Year-1 9,786 ± 915 [15] 10,356 ± 1273 [12] 10,392 ± 1212 [14] 0.286 0.549
Weight gain [g]
Δ Week-6 - birth 1,265 (1,095-1,480) [15] 1,480 (775–1,690) [13] 1,550 (1,361-1,892) [12] 0.017b 0.394
Δ Month-4 - week-6 1,734 (1,390-2,100) [15] 2,070 (1,840-2,300) [11] 1,848 (1,460-2,100) [11] 0.112 0.042a
Δ Year-1 - month-4 3,318 ± 760 [15] 3,228 ± 801 [11] 3,329 ± 666 [13] 0.936 0.937
Δ Year-1 - birth 6,337 ± 996 [15] 6,665 ± 1,220 [12] 6,765 ± 1,102 [14] 0.554 0.722
Length [cm]
Birth 51.8 ± 1.5 [15] 52.5 ± 1.4 [13] 52.3 ± 1.5 [16] 0.299 0.264
Week-6 55.6 ± 0.9 [15] 56.0 ± 1.8 [13] 56.4 ± 1.4 [12] 0.360 0.738
Month-4 63.3 ± 1.2 [15] 64.4 ± 2.0 [11] 63.7 ± 1.4 [13] 0.226 0.177
Year-1 76.5 ± 2.3 [15] 77.5 ± 2.6 [12] 76.7 ± 2.7 [14] 0.551 0.666
Ponderal index [g/cm3]
Birth 6.65 ± 0.54 [15] 6.95 ± 0.48 [13] 6.81 ± 0.51 [16] 0.291 0.287
Week-6 8.45 ± 0.55 [15] 8.86 ± 1.03 [13] 9.36 ± 0.75 [12] 0.018b 0.176
Month-4 10.21 ± 0.81 [15] 10.74 ± 1.06 [11] 11.04 ± 0.97 [13] 0.073 0.272
Year-1 12.80 ± 1.04 [15] 13.34 ± 1.38 [12] 13.52 ± 1.30 [14] 0.262 0.616
Head circumference [cm]
Birth 34.0 (34.0-35.5) [15] 35.0 (34.5-36.5) [13] 35.5(34.0-36.0) [16] 0.072 0.410
Week-6 37.5 (37.0-38.8) [15] 38.3 (37.6-39.7) [13] 38.9 (37.7-40.0) [12] 0.023b 0.096
Month-4 41.1 ± 1.2 [15] 42.1 ± 1.7 [11] 42.0 ± 1.3 [13] 0.132 0.184
Year-1 45.6 ± 1.4 [15] 47.0 ± 1.6 [12] 47.1 ± 1.7 [14] 0.072 0.105
Waist circumference [cm]
Year-1 45.1 ± 2.4 [15] 45.6 ± 4.0 [12] 45.7 ± 3.0 [14] 0.859 0.897
Data are presented as mean ± SD; otherwise skewed variables are presented as median followed by interquartile range, numbers in brackets represent number of
infants included in the analysis.
1One-way ANOVA with Sidak’s post hoc test or nonparametric Kruskal-Wallis-test with Dunn’s post hoc test.
2Statistical analyses were performed by multiple linear regression models. P-values for parameters at week-1 were adjusted for infant sex, pregnancy duration and
age at investigation. P-values at week-6, month-4 and year-1 were adjusted for infant sex, pregnancy duration, age at investigation and corresponding breastfeeding.
aP-value < 0.05 obese vs. lean group; bp-value < 0.05 obese GDM vs. lean group.
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found in the unadjusted analysis, and C-peptide
remained an independent positive predictor after full
adjustment for infant sex, pregnancy duration, pre-
pregnancy BMI, OGTT-derived AUC Glucose and gesta-
tional weight gain. Decreasing levels of maternal HMW
adiponectin and SA were significantly related to higher off-
spring PPA at week-1 in the unadjusted analysis, whereas in
the adjusted model, only maternal HMW adiponectin
remained as negative determinant. Notably, no significant
relationships were found for maternal C-peptide, HMW
adiponectin or SA with subcutaneous adipose tissues,
namely SCA (Figure 1) and SFT (Additional file 2), at
week-1. Indicated maternal parameters were no longer re-
lated to PPA at week-6, month-4 and year-1 in the fullyadjusted analyses, however we found that maternal HMW
adiponectin and SA were significantly positively related to
infant SCA only at month-4 (Additional file 2).
Discussion
Adipose tissue development within the 1st year in off-
spring born from obese and GDM mothers is poorly
investigated. This study is the first reporting compara-
tive longitudinally SFT assessment combined with com-
plementary abdominal ultrasonography of SCA and
PPA from birth to year-1 pp in offspring from obese
mothers with and without GDM and normoglycemic
lean mothers.
Our data show that offspring of obese GDM mothers
have significantly higher cord insulin levels associated
Table 3 Infant adipose tissue growth assessed by skinfold thickness measurements and ultrasonography from week-1
to year-1
Lean group Obese group Obese GDM group P-value1 Adjusted p-value2
SFT [mm]
Week-1 18.9 ± 3.1 [15] 20.3 ± 2.6 [13] 21.6 ± 2.4 [16] 0.031a 0.031a
Week-6 25.2 ± 3.7 [15] 26.1 ± 5.1 [13] 30.4 ± 3.4 [12] 0.007a,b 0.048a
Month-4 30.7 ± 6.6 [15] 31.2 ± 4.3 [11] 33.6 ± 4.8 [13] 0.336 0.258
Year-1 29.0 ± 4.3 [15] 30.3 ± 4.6 [12] 29.7 ± 4.8 [14] 0.749 0.536
Fat mass [g]3
Week-1 583 ± 139 [15] 660 ± 114 [13] 694 ± 117 [16] 0.051 0.042a
Week-6 1,008 ± 159 [15] 1,098 ± 285 [13] 1,307 ± 187 [12] 0.004a,b 0.048a
Month-4 1,581 ± 318 [15] 1,728 ± 327 [11] 1,847 ± 328 [13] 0.108 0.184
Year-1 2,260 ± 419 [15] 2,475 ± 536 [12] 2,444 ± 530 [14] 0.466 0.498
Trunk-total SFT ratio (%)4
Week-1 47.4 ± 2.5 [15] 47.2 ± 3.3 [13] 48.1 ± 2.9 [16] 0.630 0.958
Week-6 48.4 ± 3.2 [15] 49.4 ± 3.4 [13] 49.1 ± 2.4 [12] 0.648 0.528
Month-4 49.0 ± 4.1 [15] 48.9 ± 2.4 [11] 49.6 ± 3.1 [13] 0.841 0.647
Year-1 45.1 ± 2.6 [15] 44.9 ± 2.6 [12] 48.5 ± 3.3 [14] 0.002a,b 0.035a,b
SCA (mm2)5
Week-1 12.7 (9.5-15.4) [12] 16.7 (14.0-19.9) [12] 17.7 (16.8-19.4) [12] 0.020a 0.014a
Week-6 24.0 ± 6.6 [15] 26.5 ± 10.7 [13] 34.6 ± 7.9 [12] 0.008a,b 0.058a
Month-4 41.3 ± 12.8 [15] 42.9 ± 9.4 [11] 45.6 ± 12.7 [13] 0.644 0.458
Year-1 24.6 (18.6-27.7) [15] 29.0 (26.8-36.2) [12] 34.2 (22.8-43.6) [14] 0.132 0.217
PPA (mm2)5
Week-1 5.6 (4.9-7.9) [12] 7.9 (6.3-9.3) [12] 10.0 (8.9-12.2) [12] 0.001a 0.001a,b
Week-6 10.0 ± 2.7 [15] 11.4 ± 3.6 [13] 13.9 ± 2.9 [12] 0.009a 0.183
Month-4 13.5 (9.7-14.1) [15] 16.9 (12.1-18.6) [11] 15.6 (11.5-18.0) [13] 0.221 0.525
Year-1 17.5 ± 4.9 [15] 22.3 ± 7.0 [12] 20.8 ± 6.7 [14] 0.130 0.368
PPA: preperitoneal adipose tissue; SCA: subcutaneous adipose tissue; SFT: sum of the 4 skinfold thickness measurements (biceps + triceps + subscapular
+ suprailiac).
Data are presented as mean ± SD; otherwise skewed variables are presented as median followed by interquartile range; numbers in brackets represent number of
infants included in the analysis.
1One-way ANOVA with Sidak’s post hoc test or nonparametric Kruskal-Wallis-test with Dunn’s post hoc test.
2Statistical analyses were performed by multiple linear regression models. P-values for parameters at week-1 were adjusted for infant sex, pregnancy duration and
age at investigation. P-values at week-6, month-4 and year-1 were adjusted for infant sex, pregnancy duration, age at investigation and corresponding
breastfeeding status.
aP-value < 0.05 obese GDM vs. lean group; bp-value < 0.05 obese GDM vs. obese group.
3Fat mass was estimated from the sum of 4 SFTs by using the equations of Weststrate and Deurenberg [22].
4Trunk-total SFT ratio (%) was evaluated by applying the equation (subscapular + suprailiac SFT)/(sum of 4 SFTs) × 100 of Westrate et al. [23].
5SCA and PPA were measured as areas of 1-cm length according to the method of Holzhauer et al. [18]. SCA indicates mean area from axial + sagittal plane.
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http://www.biomedcentral.com/1471-2393/14/138with higher fat mass than offspring of euglycemic lean
and obese mothers. The major novel findings were that
abdominal SCA and PPA in infants from obese women
with GDM were significantly higher at week-1 and SFT
was significantly elevated at week-1 and week-6 compared
to offspring of lean mothers. Moreover, our analysis re-
vealed that neonatal PPA is highly related to PPA devel-
opment at year-1. Searching for maternal markers as
predictors for offspring adipose tissue growth and obesity
risk, we identified a significantly positive relationship for
maternal C-peptide levels and a significantly inverse
relationship for HMW adiponectin with infant PPA atweek-1. However, these associations of maternal factors
did not prolong afterwards in the first year of life.
Our data are compatible with the hypothesis proposed
by Pedersen et al. [25] indicating that fetal hyperinsuline-
mia is an adaptive process resulting from elevated mater-
nal glucose levels [6], and that fetal insulin is associated
with neonatal fat mass and growth due to the role of insu-
lin in adipogenesis and stimulation of insulin-like-growth
factor 1 (IGF-1) production [6,26]. Moreover, the data are
in line with two other studies that did not observe fetal
hyperinsulinemia in pregnancies of euglycemic obese
women [27,28]. In contrast, Catalano et al. [7] reported
Table 4 Regression of fat distribution parameters up to
year-1 on cord plasma insulin levels
Cord plasma insulin
Unadjusted analysis Adjusted analysis
N β P-value β P-value Adjusted model r2
Week-1
SFT 44 0.398 0.007 0.325 0.071 0.195; p = 0.026
SCA 36 0.464 0.004 0.390 0.039 0.310; p = 0.008
PPA 36 0.445 0.007 0.436 0.022 0.311; p = 0.008
Week-6
SFT 40 0.294 0.065 0.292 0.146 0.122; p = 0.127
SCA 40 0.335 0.035 0.241 0.217 0.163; p = 0.074
PPA 40 0.307 0.054 0.287 0.119 0.268; p = 0.014
Month-4
SFT 39 0.281 0.084 0.196 0.335 0.080; p = 0.215
SCA 39 0.175 0.287 0.056 0.794 −0.044; p = 0.615
PPA 39 0.146 0.368 0.011 0.961 −0.090; p = 0.799
Year-1
SFT 41 −0.072 0.653 −0.017 0.937 −0.080; p = 0.769
SCA 41 0.027 0.866 0.085 0.680 −0.034; p = 0.585
PPA 41 0.062 0.698 0.198 0.290 0.137; p = 0.099
β: standardized regression coefficient; PPA: preperitoneal adipose tissue; r2:
coefficient of determination; SCA: subcutaneous adipose tissue; SFT: sum of
the 4 skinfold thickness measurements (biceps + triceps + subscapular +
suprailiac). Variables for adjusted analysis: infant sex, pregnancy duration,
respective breastfeeding status, maternal pre-pregnancy BMI, AUC Glucose
(OGTT) and gestational weight gain.
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http://www.biomedcentral.com/1471-2393/14/138increased total fat mass and insulin levels in newborns
from obese mothers and thereby bringing forward insulin
resistance in utero without maternal diabetes. However, in
the study of Catalano et al. [7], OGTT was performed
in the 2nd trimester and a subsequent glucose toleranceTable 5 Regression of growth and fat mass parameters at
year-1 on respective neonatal assessments





N β P-value β P-value Adjusted model r2
Birth weight 41 0.294 0.062 0.179 0.289 0.149; p = 0.085
Birth ponderal
index
41 0.248 0.117 0.161 0.342 0.130; p = 0.109
SFT, week-1 41 −0.012 0.939 −0.082 0.666 −0.074; p = 0.746
SCA, week-1 36 0.006 0.863 −0.260 0.227 −0.260; p = 0.277
PPA, week-1 36 0.520 0.002 0.486 0.010 0.275; p = 0.027
β: standardized regression coefficient; PPA: preperitoneal adipose tissue; r2:
coefficient of determination; SCA: subcutaneous adipose tissue; SFT: sum of
the 4 skinfold thickness measurements (biceps + triceps + subscapular +
suprailiac). Variables for adjusted analysis: infant sex, pregnancy duration,
breastfeeding status at month-4, maternal pre-pregnancy BMI, AUC Glucose
(OGTT) and gestational weight gain.challenge in late pregnancy was not performed to exclude
GDM in obese women, whereas in our study glucose tol-
erance was also analyzed in late pregnancy. Our findings
on adipose tissue development and distribution within the
first year are consistent with data from several studies
reporting that GDM offspring overweight at birth dimin-
ished within the 1st year pp [9,29,30]. Interestingly, these
studies found that infant overweight reemerged at the age
of 2–3 years. In this context, GDM and reduced maternal
insulin sensitivity (IS OGTT index) were reported to be
independent predictors for both slower infant weight gain
up to month-6 [31] and reduced SFT at year-1 [32]. In con-
trast, other investigators showed increased body weight
and weight/length-ratio in 6-month-old children in rela-
tion to pregravid obesity and gestational weight gain or
found persistent increased SFT at year-1 in LGA (large for
gestational age) offspring born to GDM mothers [33,34].
Apart from maternal variables, cord plasma markers
emerged as important indicators for weight and fat mass
growth in early childhood; thus, cord insulin levels were
inversely related to infant weight gain at year-2 [35].
Moreover, elevated cord blood leptin levels were iden-
tified to be related to slower infant weight gain up to
month-6 [31], year-2 [36] and year-3 [37]. Altogether,
it is tempting to speculate that increased intrauterine and
perinatal insulin levels initiated a temporarily prolonged
increase in adipose tissues in GDM offspring up to week-6,
a postnatal time-period where GDM offspring insulin have
returned already to a normal level. Afterwards, during
subsequent time up to year-1, weight and adipose tissue
growth normalized, because these insulin-mediated effects
faded away. However, a long-term impact of maternal and
fetal hyperglycemia on later infancy and adolescence obes-
ity risk is still plausible as indicated by epidemiological
studies [11,12,38]. In addition, the impact of early postna-
tal critical periods of programming was highlighted by
Péneau et al. [39] showing that high infant BMI at year-1
and early rapid infant weight gain were risk factors for the
development and persistence of overweight at the age of
7–9 years.
We found that neonatal PPA at week-1 is an inde-
pendent predictor for PPA at infant age of 1 year.
These data on PPA may mirror intrauterine influences
on early adipose tissue development and programming
effects with potentially sustained unfavorable effects at
later stages in infancy or childhood. This proposed re-
lationship warrants evaluation in future studies with
larger cohorts. The importance of investigating specific
changes in early adipose tissue distribution as we per-
formed in this study is supported by recent insights
into distinct neonatal fat depots assessed by magnetic
resonance tomography (MRT) [40,41]. The authors de-
scribed significantly increased intra-hepatocellular lipids
in newborns in relation to pregravid BMI and GDM, but
Figure 1 (See legend on next page.)
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Figure 1 Regression of PPA and SCA at week-1 on maternal plasma C-peptide and adiponectin levels at 3rd trimester. Maternal
C-peptide (A), HMW adiponectin (B) and SA (C) are presented in relation to neonatal PPA and SCA, respectively. β: unadjusted standardized
regression coefficient. βadj: standardized regression coefficient adjusted for the variables infant sex, pregnancy duration, maternal pre-pregnancy
BMI, AUC Glucose (OGTT) and gestational weight gain. The plotted regression lines indicate the results of the unadjusted analyses. HMW: high
molecular weight; Log: logarithmic; PPA: preperitoneal adipose tissue; SA: HMW-total adiponectin ratio; SCA: subcutaneous adipose tissue; open
circles: lean group; black circles: obese group; open triangles: obese GDM group.
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of maternal obesity on abdominal fat in neonates [40,41].
Brumbaugh et al. [40] did not find a difference in intra-
abdominal fat per body length in infants of obese mothers
with GDM, whereas Modi et al. [41] showed the positive
relationship between maternal BMI and abdominal fat in
newborns, but did not discriminate between subcutaneous
and intra-abdominal fat. Apart from that, PPA was dem-
onstrated to be a good approximation for intra-abdominal
fat assessed by computer tomography (CT) [19].
More recently, research interest has started to par-
ticularly focus on comprehensively analyzing the distri-
bution and accumulation of distinct fat depots in the
body, especially the abdominal fat in longitudinal stud-
ies and their relation to metabolic biomarkers. Our
data indicate that cord plasma insulin was positively
related to neonatal SFT and fat mass that is in line with
the results reported by Brunner et al. [35]. Importantly,
for the first time, we showed that cord insulin levels
emerged as independent predictors for PPA and SCA at
week-1 after birth. Interestingly, Tamura et al. [42] have
shown that insulin levels are strongly related to PPA and
SCA in 9-15-year old children. In addition, Cnop et al.
[43] reported that insulin sensitivity was inversely corre-
lated with visceral, but not with subcutaneous fat, whereas
leptin levels were stronger related to subcutaneous fat
amount in adults. Moreover, increased PPA was recently
determined as cardiovascular risk factor in obese chil-
dren [15] and non-obese adults [16,44]. Considering
these studies and our data on cord plasma insulin levels
with SCA and PPA in neonates, we speculate that in-
creased neonatal PPA and SCA results from insulin-
mediated early metabolic malprogramming which may
have the potency to contribute to adverse effects later in
life. Therefore, increased PPA at birth might be indicative
for both later obesity and cardiovascular risk.
With regard to maternal lipid levels during pregnancy
and the recurrently described hypertriglyceridemia in
GDM [45,46], we found that total and LDL cholesterol
levels were significantly lower in obese women than in
the lean group, whereas triglyceride levels were similar in
all groups at the 3rd trimester. In addition these maternal
differences were not reflected in cord plasma where chol-
esterol and triglyceride levels were rather alike. Our data
on both maternal cholesterol and triglyceride levels for all
study groups are consistent with several studies [47-52].According to Meyer et al. [51] and Scifres et al. [52], obese
women exhibit higher levels for triglycerides, total and
LDL cholesterol at the beginning of pregnancy than their
lean counterparts, but these differences decrease towards
term reaching similar or even slightly lower levels in obese
women. Regarding the relation between maternal and cord
LDL and total cholesterol levels, published data are not
consistent, and sometimes even opposing levels between
newborn and mother have been described [49,53].
In pregnant women, it is known that HMW and total
adiponectin are closely related to glycemia, insulin
sensitivity and β-cell function [54]. We found that
obese mothers, characterized by hyperinsulinemia and
increased HOMA-IR-index, had decreased HMW adi-
ponectin and SA which is in line with recent data from
animal and clinical studies reporting that insulin is a
negative regulator of adiponectin, preferentially HMW
oligomer, secretion [55]. In contrast, in the present
study, total and HMW adiponectin levels in cord plasma
were not affected by maternal obesity and GDM, as has
been described [7,56,57]. Umbilical cord total and HMW
adiponectin levels have been associated with neonatal
weight, ponderal index and body fat [56,58-60], but similar
associations did not emerge in our pilot study (Additional
file 3). There was also no significant association between
insulin and adiponectin levels in neonates (Additional
file 3) indicating that the regulation of fetal adiponectin
might be different from adult metabolism [59].
Another important finding of our study was that ma-
ternal C-peptide levels were positively and maternal
HMW adiponectin levels inversely related to infant PPA
at week-1. This strongly suggests that maternal insulin
and HMW adiponectin levels are major regulators of ma-
ternal metabolism which might impact fetal and newborn
PPA growth. Moreover, the observed significant relation-
ships of maternal C-peptide and HMW adiponectin levels
with PPA, but not with subcutaneous adipose tissues (SFT
and SCA) at week-1 implicate that changes in maternal in-
sulin sensitivity indirectly influences the growth of specific
fat compartments during fetal development observed in
the neonates.
Although this pilot study was limited by a small partici-
pant number and imbalanced offspring sex distribution in
the group of obese mothers with GDM as well as the short
observational follow-up period, it emphasizes the need to
apply ultrasonography as useful method to generate new
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growth and distribution and their association to blood
markers and obesity risk.
Conclusion
This study shows that maternal pregravid obesity combined
with GDM but not maternal obesity alone led to offspring
neonatal hyperinsulinemia and increased offspring fat mass
until week-6. These findings together with the knowledge
from published reports on lean pregnant women with
GDM corroborate GDM as the pivotal cause of newborn
hyperinsulinemia. However, the observed short adverse
impact of intrauterine hyperglycemia on neonatal adipose
tissue growth seems to vanish within the first year of life.
Importantly, the identification of maternal C-peptide and
HMW adiponectin levels as novel potential predictors for
distinct PPA growth in newborns might be indicative for
obesity risk in later life. Recently, increased PPA was de-
termined as cardiovascular risk factor in obese children
and non-obese adults. Therefore, increased PPA at birth
might be not only indicative for later obesity risk, but also
for cardiovascular risk in adulthood. These aspects should
be evaluated in relation to the treatment of pregravid
obesity and GDM by dietary and lifestyle intervention
studies in larger cohorts, since there is an urgent need for
the reduction of offspring obesity and the identification of
reliable predictors for offspring obesity risk and its relation
to cardiovascular risk factors.
Additional files
Additional file 1: Figure S1. Inter-observer agreement for the
ultrasonographic measurement of preperitoneal and subcutaneous fat
assessed by the Bland-Altman plot. From 120 randomly chosen
ultrasonographic images, 180 subcutaneous and preperitoneal adipose
tissue areas were independently assessed by a second observer. The mean
of the differences (bias) was −0.17 mm2 and the Limits of Agreement
were −0.65 mm2 (mean - 2 SD) and 0.31 mm2 (mean + 2 SD). SD:
standard deviation.
Additional file 2: Table S1. Regression of infant fat distribution
parameter at all ages investigated on plasma maternal C-peptide and
adiponectin levels at 3rd trimester.
Additional file 3: Table S2. Spearman and partial correlations of cord
plasma adiponectin levels with cord plasma insulin and newborn adipose
tissue parameters.
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